Inhibitors targeting vascular endothelial growth factor receptor kinases and cyclin-dependent kinases

Abstract

Merck claims inhibitors of vascular endothelial growth factor (VEGF) receptor tyrosine kinases and cyclin-dependent serine/threonine kinases based on an N-(thiazol-2-yl)pyrimidin-4-amine core. The claimed compounds are similar to recently published kinase inhibitors from Merck with a pyridine-2-amine core. The compounds of the present application are indicated to be useful for treating cancer and additional diseases through disruption of kinase-driven signal transduction pathways, disruption of cell-cycle progression, or both.

• angiogenesis
• cyclin-dependent kinase (CDK)
• endothelial cell
• kinase insert domain containing receptor (KDR)
• tyrosine kinase inhibitor
• vascular endothelial growth factor (VEGF)